Modern Possibilities of Hormone Targeted Therapy in Metastatic Receptor-Positive HER2-Negative Breast Сancer. A Clinical Case
The article considers a clinical case that clearly demonstrates the positive effect of a combination of targeted therapy, including CDK4/6i (ribociclib), and an aromatase inhibitor in the first line of therapy in a premenopausal patient with hormonal receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer.
Authors
- Julia Shevchenko (ORCID: https://orcid.org/0000-0001-8773-0599)
- S.A. Belyaeva
- A.S. Shatokhina (ORCID: https://orcid.org/0000-0001-7719-370X)
- М. Г. Леонов (ORCID: https://orcid.org/0000-0001-5573-7681)
Publication Details
- Journal
- Effective Pharmacotherapy
- Published
- 2024-08-08
- DOI
- https://doi.org/10.33978/2307-3586-2024-20-22-14-16
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00